Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

Rang in Aktien #3289
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Aktienkurs
$81.40
Marktkapitalisierung
$5.39B
Veränderung (1 Tag)
1.86%
Veränderung (1 Jahr)
205.46%
Land
US
Handel Oruka Therapeutics, Inc. (ORKA)

Kategorie

Healthcare
Aktien-Split-Historie für Oruka Therapeutics, Inc. (ORKA)
Die Aktie Oruka Therapeutics, Inc. (Symbol: ORKA) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 22, 2026 statt.
Eine ORKA-Aktie, die vor dem Oct 22, 2026 gekauft wurde, entspricht heute 0 ORKA-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 1 x100
BE